

Dr. Lal PathLabs Limited records revenue of Rs 266.0 Cr in Q1 FY 2020-21

New Delhi, India, July 31, 2020 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2020

Consolidated Performance Highlights: Q1 FY 2020-21 vs Q1 FY 2019-20

**Revenue: Rs 266.0 Cr,
Normalised EBITDA at Rs 54.0 Cr,
Normalised EBITDA margins at 20.3%,
PBT at Rs 38.1 Cr with margin at 14.3%, and
PAT Rs 28.4 Cr with margin at 10.7%**

- Operating Revenue declined by 20.6% in Q1 FY21 to Rs. 266.0 Cr vs Rs 335.2 Cr in Q1 FY20. Underlying patient volume decline is 28.4% during the quarter
- Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q1 FY21 is at Rs. 54.0 Cr Vs Rs 99.0 Cr in the same quarter last year
- PBT is at Rs 38.1 Cr in Q1 FY21 vs Rs 89.4 Cr. in Q1 last year
- Profit after Tax in Q1 FY21 at Rs. 28.4 Cr as compared to Rs 59.1 Cr in Q1 last year

Financial Overview (Consolidated) in Rs Cr

Particulars	Q1 FY21	Q1 FY20	Gr %	FY20
Revenue	266.0	335.2	-20.6%	1330.4
Expenditure	217.6	240.1		986.8
EBITDA	48.4	95.1	-49.1%	343.6
Adj for Stock based compensation & CSR cost	5.6	3.9		22.0
Normalised EBITDA	54.0	99.0	-45.5%	365.6
<i>Normalised Margins</i>	<i>20.3%</i>	<i>29.5%</i>		<i>27.5%</i>
Other income	11.4	14.4		55.0
PBT	38.1	89.4	-57.4%	310.5
<i>Margins</i>	<i>14.3%</i>	<i>26.7%</i>		<i>23.3%</i>
PAT	28.4	59.1	-51.9%	227.6
<i>Margins</i>	<i>10.7%</i>	<i>17.6%</i>		<i>17.1%</i>
EPS (Basic)	3.45	7.14	-51.7%	27.42
EPS (Diluted)	3.44	7.13	-51.7%	27.37



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Mittali Bharti
Adfactors PR

+91 9871154558
mittali.bharti@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.